Anabolic resistance does not explain sarcopenia in patients with type 2 diabetes mellitus, compared with healthy controls, despite reduced mTOR pathway activity - Cuthbertson, D J; Babraj, J; Leese, G (Clin Nutr. Elsevier Ltd, 2016)
et al.